Zach Frank, Mueller Alexandra, Gessner André
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
PLoS One. 2015 Nov 3;10(11):e0142211. doi: 10.1371/journal.pone.0142211. eCollection 2015.
In vitro differentiation into functional osteoclasts is routinely achieved by incubation of embryonic stem cells, induced pluripotent stem cells, or primary as well as cryopreserved spleen and bone marrow-derived cells with soluble receptor activator of nuclear factor kappa-B ligand and macrophage colony-stimulating factor. Additionally, osteoclasts can be derived from co-cultures with osteoblasts or by direct administration of soluble receptor activator of nuclear factor kappa-B ligand to RAW 264.7 macrophage lineage cells. However, despite their benefits for osteoclast-associated research, these different methods have several drawbacks with respect to differentiation yields, time and animal consumption, storage life of progenitor cells or the limited potential for genetic manipulation of osteoclast precursors. In the present study, we therefore established a novel protocol for the differentiation of osteoclasts from murine ER-Hoxb8-immortalized myeloid stem cells. We isolated and immortalized bone marrow cells from wild type and genetically manipulated mouse lines, optimized protocols for osteoclast differentiation and compared these cells to osteoclasts derived from conventional sources. In vitro generated ER-Hoxb8 osteoclasts displayed typical osteoclast characteristics such as multi-nucleation, tartrate-resistant acid phosphatase staining of supernatants and cells, F-actin ring formation and bone resorption activity. Furthermore, the osteoclast differentiation time course was traced on a gene expression level. Increased expression of osteoclast-specific genes and decreased expression of stem cell marker genes during differentiation of osteoclasts from ER-Hoxb8-immortalized myeloid progenitor cells were detected by gene array and confirmed by semi-quantitative and quantitative RT-PCR approaches. In summary, we established a novel method for the quantitative production of murine bona fide osteoclasts from ER-Hoxb8 stem cells generated from wild type or genetically manipulated mouse lines. These cells represent a standardized and theoretically unlimited source for osteoclast-associated research projects.
通过将胚胎干细胞、诱导多能干细胞、原代以及冷冻保存的脾脏和骨髓来源的细胞与核因子κB受体激活剂配体和巨噬细胞集落刺激因子一起孵育,可常规实现体外分化为功能性破骨细胞。此外,破骨细胞可来源于与成骨细胞的共培养,或通过向RAW 264.7巨噬细胞系细胞直接施用核因子κB受体激活剂配体而获得。然而,尽管这些不同方法对破骨细胞相关研究有益,但在分化产量、时间和动物消耗、祖细胞的储存寿命或破骨细胞前体的基因操作潜力有限方面存在若干缺点。因此,在本研究中,我们建立了一种从鼠ER-Hoxb8永生化髓系干细胞分化破骨细胞的新方案。我们从野生型和基因操作小鼠品系中分离并永生化骨髓细胞,优化破骨细胞分化方案,并将这些细胞与传统来源的破骨细胞进行比较。体外产生的ER-Hoxb8破骨细胞表现出典型的破骨细胞特征,如多核化、上清液和细胞的抗酒石酸酸性磷酸酶染色、F-肌动蛋白环形成和骨吸收活性。此外,在基因表达水平上追踪破骨细胞分化的时间进程。通过基因芯片检测并经半定量和定量RT-PCR方法证实,在从ER-Hoxb8永生化髓系祖细胞分化破骨细胞的过程中,破骨细胞特异性基因表达增加,干细胞标记基因表达减少。总之,我们建立了一种从野生型或基因操作小鼠品系产生的ER-Hoxb8干细胞定量产生鼠真性破骨细胞的新方法。这些细胞代表了破骨细胞相关研究项目的标准化且理论上无限的来源。